News | Artificial Intelligence | March 02, 2017

IBM Debuts First Cognitive Imaging Offering from Watson Health

Company also announces expansion of Watson Health Medical Imaging Collaborative to 24 members worldwide

IBM, Watson Health, Imaging Clinical Review, first cognitive imaging offering, HIMSS17

March 2, 2017 — IBM at the 2017 Healthcare Information and Management Systems Society Conference and Exhibition (HIMSS17) introduced IBM Watson Imaging Clinical Review, the first cognitive imaging offering from Watson Health. The company also announced the expansion of the Watson Health medical imaging collaborative to 24 organizations worldwide, adding clinical and industry expertise for the worldwide initiative finding ways to use medical imaging to identify and predict the risk of cancer, diabetes and diseases of the eye, brain, breast, heart and related conditions.

New collaborative members include:

  • Froedtert & the Medical College of Wisconsin;
  • IDx LLC;
  • PrivaCors;
  • Strategic Radiology;
  • Sutter Health;
  • Pacific Radiology Group;
  • University of Michigan; and
  • University of Virginia Health System.

They join founding members that include:

  • Agfa HealthCare;
  • Anne Arundel Medical Center;
  • Baptist Health South Florida;
  • Eastern Virginia Medical School;
  • Hologic Inc.;
  • ifa systems AG;
  • Inoveon;
  • Radiology Associates of South Florida;
  • Sentara Healthcare;
  • Sheridan Healthcare;
  • Topcon;
  • University of California San Diego Health;
  • University of Miami Health System;
  • University of Vermont Health Network;
  • vRad, a Mednax company; and
  • Merge, an IBM company.

“The medical imaging collaborative is vital to Watson’s ongoing training and the development of cognitive imaging solutions to address the world’s pressing health challenges,” said Anne Le Grand, vice president of Imaging for Watson Health. She added that members of the collaborative helped design and curate data for Watson Imaging Clinical Review.

The offering reviews medical data to help healthcare providers identify the most critical cases that require attention. The first application for the offering is cardiovascular disease, starting with a common condition called aortic stenosis (AS). AS, which affects 1.5 million Americans, occurs when the aortic valve in the heart is narrowed, impeding blood flow to the rest of the body and causing shortness of breath, tiredness, and chest pain. A pilot study found that Watson Imaging Clinical Review was able to help hospital personnel identify potential AS patients who had not been previously flagged for follow-up cardiovascular care.

Using Watson Imaging Clinical Review, hospital administrators may identify cases where follow-up care is warranted and assure electronic medical record (EMR) information is complete. It uses cognitive text analytics to read structured and unstructured information in a cardiologist’s medical report, combines that with a variety of data from other sources (e.g. EMR problem list), and extracts relevant information to verify key data, including the diagnosis, is accurately reflected throughout the health record.

“Watson Imaging Clinical Review is the type of targeted AI [artificial intelligence]-driven tool that providers could put to use to help them standardize care delivered across their organization, and gradually build a critical mass of reproducible results from their patient population. In doing so, it can support a population health-driven approach to personalized care,” said Nadim Michel Daher, a medical imaging and informatics analyst for Frost & Sullivan.

“Out of the gate, this type of cognitive tool may provide big benefits to hospitals and doctors, providing insights we don’t currently have and doing so in a way that fits how we work,” said Ricardo C. Cury, M.D., director of cardiac imaging at Baptist Health of South Florida and chairman and CEO of Radiology Associates of South Florida.

IBM plans to supplement the release of this offering with nine additional cardiovascular conditions, such as myocardial infarctions (heart attacks), valve disorders, cardiomyopathy (disease of the heart muscle) and deep vein thrombosis.

Read the feature story "How Artificial Intelligence Will Change Medical Imaging."

For more information: www.ibm.com/watsonhealth

Related Content

Qure.ai, a leading healthcare AI startup
News | Artificial Intelligence | February 27, 2020
February 27, 2020 — Qure.ai, a leading healthcare AI startup has ann
Emagine Solutions Technology's VistaScan portable ultrasound enables doctors to enhance patient care. Clinicians can diagnose in moments, saving time and lives at a fraction of the cost of a cart ultrasound machine

Emagine Solutions Technology's VistaScan portable ultrasound enables doctors to enhance patient care. Clinicians can diagnose in moments, saving time and lives at a fraction of the cost of a cart ultrasound machine. Photo credit: Tech Parks Arizona

News | Ultrasound Imaging | February 27, 2020
February 27, 2020 — Emagine Solutions Technology, an award-winnin
In a study of more than 1,000 patients published in the journal Radiology, chest CT outperformed lab testing in the diagnosis of 2019 novel coronavirus disease (COVID-19) #COVID19 #COVID-2019 #2019nCoV #COVID-19

Chest CT images of a 29-year-old man with fever for 6 days. RT-PCR assay for the SARS-CoV-2 using a swab sample was performed on Feb. 5, 2020, with a positive result. (A column) Normal chest CT with axial and coronal planes was obtained at the onset. (B column) Chest CT with axial and coronal planes shows minimal ground-glass opacities in the bilateral lower lung lobes (yellow arrows). (C column) Chest CT with axial and coronal planes shows increased ground-glass opacities (yellow arrowheads). (D column) Chest CT with axial and coronal planes shows the progression of pneumonia with mixed ground-glass opacities and linear opacities in the subpleural area. (E column) Chest CT with axial and coronal planes shows the absorption of both ground-glass opacities and organizing pneumonia. Image courtesy of Radiology

News | Computed Tomography (CT) | February 26, 2020 | Melinda Taschetta-Millane and Dave Fornell
February 26, 2020 — In a study of m
 over the course of a week and a half #coronavirus #COVID19 #COVID-2019 #2019nCoV

29-year old male with unknown exposure history, presenting with fever and cough, ultimately requiring intensive care unit admission. (a) Axial thin-section non-contrast CT scan shows diffuse bilateral confluent and patchy ground-glass (solid arrows) and consolidative (dashed arrows) pulmonary opacities. (b) The disease in the right middle and lower lobes has a striking peripheral distribution (arrow). Image courtesy of Radiology 

News | Computed Tomography (CT) | February 26, 2020
February 26, 2020 — Mount Sinai Health System physicians—the
Images in a 41-year-old woman who presented with fever and positive polymerase chain reaction assay for the 2019 novel coronavirus (2019-nCoV) #coronavirus #nCoV2019 #2019nCoV #COVID19

Images in a 41-year-old woman who presented with fever and positive polymerase chain reaction assay for the 2019 novel coronavirus (2019-nCoV). Three representative axial thin-section chest CT images show multifocal ground glass opacities without consolidation. Three-dimensional volume-rendered reconstruction shows the distribution of the ground-glass opacities (arrows). Image courtesy of the Radiological Society of North America (RSNA)

News | Radiology Imaging | February 25, 2020
February 24, 2020 — The U.S.
Carestream’s state-of-the-art OnSight 3D Extremity System
News | Computed Tomography (CT) | February 25, 2020
February 25, 2020 — Carestream’s state-of-the-art...
Sponsored Content | Videos | Artificial Intelligence | February 21, 2020
In Artificial Intelligence at RSNA 2019, ITN Contributing Editor Greg Freiherr offers an overview of artificial intel